KRAS and neoplasm: Furthermore, as clinical trials continue to rely on preclinical data, it is crucial to perform studies with the most rigorous and relevant models.209,210 We believe that the field is primed to leverage our growing knowledge of the PDAC TME, along with the excitement of new targeted strategies against tumor-intrinsic properties (eg, KRAS), to improve overall patient outcomes against this lethal cancer.